Navigation Links
Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B

Diana Davis, PhD, Aiguo Zhang, PhD, Chloe Etienne, Ivan Huang, and Michele Malit, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive, Hercules, CA 94547 USA


Introduction
Bio-Plex cytokine assays are bead-based multiplex sandwich immunoassays. The concentrations of analytes in a Bio-Plex cytokine immunoassay are quantitated using a calibration or standard curve. More specifically, a series of known concentrations of an analyte is used to construct a plot of signal intensity vs. concentration. The plot is mathematically modeled to derive an equation that may be used to predict the concentrations of unknown samples. The type of mathematical or curve-fitting model as well as the fit of the model have a direct effect on the accuracy of the results. Therefore, curve fitting is a critical component of immunoassay performance. In this technical note, curvefitting methods as well as methods used to determine the quality of the curve fitting are discussed. Advantages and disadvantages of each method and the effects on the predicted cytokine concentrations are illustrated using representative Bio-Plex cytokine assay data.


Methods of Curve Fitting
Linear Regression
The simplest method for determining concentrations from a standard curve is to construct a plot of the concentration vs. the response using the linear portion of the response curve. This method has been used traditionally to quantitate results of ELISA and other immunoassays (Nix and Wild 2001). An example of a GM-CSF Bio-Plex cytokine assay plotted using a linear regression is shown in Figure 1. The R2 value is used to determine the overall goodness of the linea
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8

Related biology technology :

1. Principles and applications of electrical cell fusion
2. Principles and applications of electrical cell fusion
3. Identification of Nonspecific Products Using Melt-Curve Analysis on the iCycler iQ Detection System, Rev A
4. Real-Time PCR/Melt-Curve Analysis: SNP Detection With FRET, Rev A
5. Mx4000 Multiplex Quantitative PCR System*,PPP
6. QIAGEN Multiplex PCR Handbook
7. QIAGEN Multiplex PCR Kit
8. Real-Time Multiplex PCR from Genomic DNA Using the iCycler iQ Detection System
9. Correlation of Bio-Plex Suspension Array Reader Validation With Multiplex Cytokine Assay Performance, Rev A
10. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
11. Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays

Post Your Comments:
(Date:11/23/2009)...ewswire/-InimexPharmaceuticals,Inc.announcedtodayt...tandCEO. ,, Abramsbringsmorethan25yearsofdrugdi...ventorofthenuclearmedicineimagingagent,Cardiolite,...wasManager,BiomedicalResearchWorldwide.In1996,Abra...esidentandCEOfrom1996to2006.AnorMEDdiscoveredandde...
(Date:11/20/2009)...untries have an opportunity to take the lead in tw...e University of Valencia (UV), working together wi...tive fabric of the Spanish biotechnology industry....ectors have more clout than those in English-speak...d and plants has been overlooked by the leading co...
(Date:11/20/2009)...20 Cell Therapeutics, In...at the Ninth Circuit Court of Appeals reversed a U... be allowed to pursue all of its claims against Th...t Court for trial. CTI filed a complaint against ...ment consultant for CTI,s product TRISENOX, in 200...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- Omeros Corporation (Nasda...ults for the third quarter ended September 30, 200...Omeros reported a net loss of $3.9 million, or $1....llion, or $2.54 per share, for the same period in ..., the Company reported a net loss of $15.5 million...
Breaking Biology Technology:Inimex Announces Appointment of New CEO 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8
... ultra-high definition has potential to revolution..., there was a glimpse into the,future of women,s h...gery,that was recorded for the first time using "4...mally Invasive Gynecology hosted by the AAGL. AAGL...cialists in minimally,invasive gynecological techn...
...t. 30 Nutrition 21, Inc.,(Nasdaq: NXXI ) today a...,president and general manager of the Company,s Di...s. McWilliams has more than 22 years of,experience...lopment within,the direct response industry. Mrs. ...development, sales strategy, vendor operations and...
...Oct. 30 Insmed Inc. (Nasdaq:,INSM), a developer o...y,reported results for the third quarter and nine-...ighlights, -- Follow-on Biologics Program ...dicines and Healthcare products Regulator...tudy for the Company,s second follow-on biologic ...
Other Biology Technology:Women's Surgery Recorded for the First Time on '4K' Digital Cinema is Presented at the AAGL Congress 2Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response 2Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 2Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 4Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 5Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 6Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 7Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 8Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 9Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 10
(Date:11/21/2009)...newswire / - KINAXO Biotechnologies GmbH announc...o new investors in the company, Leifina and Conmit...n Schumacher has been elected as a new member of t...s Axel Ullrich, Hellmut Kirchner, Manfred Ferber a...ntain Partners, BioM, High-Tech Grnderfonds, the M...
(Date:11/20/2009)...out the health benefits of having a life partner. ...re amino acids known as cysteines are much more vu... with other cysteines. , Now, researchers at the...Belgium, have discovered a new antioxidant system ...rs in the Nov. 20 issue of the journal Science . ...
(Date:11/20/2009)...abstracts to the World Congress on Osteoporosis 20...devoted to all aspects of osteoporosis and osteoar...ll be held in Florence, Italy from May 5-8, 2010. ...line at http://www.iofwco-ecceo10.org , The s...d ESCEO are pleased to announce that seven special...
Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3Saving the single cysteine: New antioxidant system found 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Typeamom net on Smart Goals for Weight Loss 55025 1Right Match of Drug Doctor Can Boost Reflux Outcomes 55021 1Right Match of Drug Doctor Can Boost Reflux Outcomes 55021 2Right Match of Drug Doctor Can Boost Reflux Outcomes 55021 3New Study of House Health Care Reform Bill 3A Texas Faces Over 242 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55018 1New Study of House Health Care Reform Bill 3A Texas Faces Over 242 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55018 2
..., 2008 A discovery by Canada-U.S. biophysicists w...n to little ,nano-machines, or ,nano-valves, in ou...tic illnesses that attack muscles, the central ner...current issue of the Proceedings of the National ...e Universit de Montral and the University of Chica...
...stmas, and make way for a "green" holiday. Here ar...ronmentally friendly, courtesy of the American Che...c society, and the ACS Green Chemistry Institute. ...sign of chemical products and processes that elimi...To reduce your own personal carbon footprint and n...
... and hormone treatment for infertility give an inc... This comes from a new study from the Norwegian I...time mothers from the Norwegian Mother and Child C... Normal risk , First-time mothers who had not... 5.2 % risk of pre-eclampsia. , Risk after mis...
Other Biology News:Researchers advance knowledge of little 'nano-machines' in our body 2Miscarriage and infertility treatment increase pre-eclampsia risk 2
Normal Porcine Serum from Equitech-Bio
Anti-Foam Reagent from Promega
Viral CCI, Unconjugated, Fc Chimera from R&D Systems
GENOMIPHI V2 DNA AMP KIT 25RXN from GE Healthcare, formerly Amersham Biosciences
Biology Products: